Newly Published
Perioperative Medicine  |   April 2017
Triggering Receptor Expressed on Myeloid Cells 2, a Novel Regulator of Immunocyte Phenotypes, Confers Neuroprotection by Relieving Neuroinflammation
Author Notes
  • From the Departments of Anesthesiology (Q.Z., J.J., S.S., D.Z., L.M., T.J., F.B., L.X.), Orthopedic Surgery (F.L.), and Geriatrics (X.C.), Xijing Hospital, Fourth Military Medical University, Xi’an, China and Department of Anesthesiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China (Q.Z., Q.W.).
  • Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal’s Web site (www.anesthesiology.org).
    Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal’s Web site (www.anesthesiology.org).×
  • Q.Z., F.L., and X.C. contributed equally to this article.
    Q.Z., F.L., and X.C. contributed equally to this article.×
  • Submitted for publication October 20, 2016. Accepted for publication March 7, 2017.
    Submitted for publication October 20, 2016. Accepted for publication March 7, 2017.×
  • Research Support: Supported by grant No. 81473488 from the National Natural Science Foundation of China, Beijing, China; grant No. 81529004 from the Overseas Hong Kong and Macao Scholars Collaborated Researching Fund, Beijing, China; and grant No. 2014 CB543202 from the National Key Basic Research and Development Program, Beijing, China.
    Research Support: Supported by grant No. 81473488 from the National Natural Science Foundation of China, Beijing, China; grant No. 81529004 from the Overseas Hong Kong and Macao Scholars Collaborated Researching Fund, Beijing, China; and grant No. 2014 CB543202 from the National Key Basic Research and Development Program, Beijing, China.×
  • Competing Interests: The authors declare no competing interests.
    Competing Interests: The authors declare no competing interests.×
  • Correspondence: Address correspondence to Dr. Wang: Department of Anesthesiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China. dr.wangqiang@139.com. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. Anesthesiology’s articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.
Article Information
Perioperative Medicine / Cardiovascular Anesthesia / Central and Peripheral Nervous Systems / Infectious Disease / Pharmacology
Perioperative Medicine   |   April 2017
Triggering Receptor Expressed on Myeloid Cells 2, a Novel Regulator of Immunocyte Phenotypes, Confers Neuroprotection by Relieving Neuroinflammation
Anesthesiology Newly Published on April 13, 2017. doi:10.1097/ALN.0000000000001628
Anesthesiology Newly Published on April 13, 2017. doi:10.1097/ALN.0000000000001628
Abstract

Background: Microglia can not only detrimentally augment secondary injury but also potentially promote recovery. However, the mechanism underlying the regulation of microglial phenotypes after stroke remains unclear.

Methods: Mice were subjected to middle cerebral artery occlusion for 60 min. At 3 days after reperfusion, the effects of activation and suppression of triggering receptor expressed on myeloid cells 2 on immunocyte phenotypes (n = 5), neurobehavioral scores (n = 7), infarct volumes (n = 8), and neuronal apoptosis (n = 7) were analyzed. In vitro, cultured microglia were exposed to oxygen–glucose deprivation for 4 h. Inflammatory cytokines, cellular viability (n = 8), neuronal apoptosis (n = 7), and triggering receptor expressed on myeloid cells 2 expression (n = 5) were evaluated in the presence or absence of triggering receptor expressed on myeloid cell-specific small interfering RNA or triggering receptor expressed on myeloid cells 2 overexpression lentivirus.

Results: Triggering receptor expressed on myeloid cells 2 expression in the ischemic penumbra peaked at 3 days after ischemia–reperfusion injury (4.4 ± 0.1-fold, P = 0.0004) and was enhanced in interleukin-4/interleukin-13–treated microglia in vitro (1.7 ± 0.2-fold, P = 0.0119). After oxygen–glucose deprivation, triggering receptor expressed on myeloid cells 2 conferred neuroprotection by regulating the phenotypic conversion of microglia and inflammatory cytokine release. Intraperitoneal administration of triggering receptor expressed on myeloid cells 2 agonist heat shock protein 60 or unilateral delivery of a recombinant triggering receptor expressed on myeloid cells 2 lentivirus into the cerebral ventricle induced a significant neuroprotective effect in mice (apoptotic neurons decreased to 31.3 ± 7.6%; infarct volume decreased to 44.9 ± 5.3%). All values are presented as the mean ± SD.

Conclusions: Activation or up-regulation of triggering receptor expressed on myeloid cells 2 promoted the phenotypic conversion of microglia and decreased the number of apoptotic neurons. Our study suggests that triggering receptor expressed on myeloid cells 2 is a novel regulator of microglial phenotypes and may be a potential therapeutic target for stroke.